Supplementary Online Content

Kannankeril PJ, Moore JP, Cerrone M, et al. Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial. *JAMA Cardiol.* Published online May 10, 2017. doi:10.1001/jamacardio.2017.1320

eTable 1. Results of Exercise Tests

eTable 2. Adverse Events

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Results of Exercise Tests

	Baseline (n=13)	*P* Value (Baseline vs Placebo	Placebo (n=12)	*P* Value (Placebo vs Flecainide	Flecainide (n=13)	*P* Value (Flecainide vs Baseline
Resting HR (bpm)	56 (42-69)	.06	62 (50-69)	.24	54 (47-79)	.75
Peak HR (bpm)	154 (103-196)	.99	150 (107-203)	.02	132 (108-196)	.01
Exercise time (seconds)	651 (419-782)	.84	612 (262-786)	>.991	642 (407-765	.38
Maximum workload (calculated VO2 max)	36 (23-47)	.96	33 (16-47)	.93	38.5 (22-46)	.61

Data are presented as median and range. VO2 calculated from exercise time on Bruce protocol (n=12 baseline, n=11 placebo, n=12 flecainide) using VO2max (ml/kg/min) = $14.76 - (1.379 \times T) + (0.451 \times T^2) - (0.012 \times T^3)$.

eTable 2. Adverse Events

Serious Adverse Event	Study Drug	Relation to Study Drug	Outcome/Comments
Suicidal ideation requiring hospitalization*	Placebo	Unlikely	Resolved in 2 days.
ICD infection requiring removal and replacement	Placebo	Unlikely	
Back pain after previous spinal surgery*	Placebo	Unlikely	Resolved after second spinal surgery
Allergic reaction to topical antibiotic used for acne	Flecainide	Unlikely	Resolved after discontinuation of topical antibiotic
Supraventricular tachycardia	Placebo	Unlikely	Episode of atrial tachycardia on ICD prompted electrophysiology study without ablation
Vasovagal Syncope without arrhythmias on ICD	Flecainide	Unlikely	Brief loss of consciousness after shower

* The subjects reporting these events during the trial had a history of these symptoms predating study participation.